Cohen-Hallaleh V, Guo L, Hosseini-Nik H, Razaghi Kashani N, Menezes R, Jhaveri K
Joint Department of Medical Imaging, University Health Network, University of Toronto, 610 University Ave., 3-957, Toronto, ON M5G 2M9, Canada.
Joint Department of Medical Imaging, University Health Network, University of Toronto, 610 University Ave., 3-957, Toronto, ON M5G 2M9, Canada.
Clin Radiol. 2017 Nov;72(11):994.e1-994.e8. doi: 10.1016/j.crad.2017.06.005. Epub 2017 Jun 30.
To evaluate retrospectively the impact of injection flow rate on arterial phase image degradation in liver magnetic resonance imaging (MRI) with gadoxetic acid (Gd-EOB-DTPA) compared to gadobutrol.
Two hundred consecutive patients who had undergone liver MRI were enrolled in this Health Insurance Portability and Accountability Act (HIPAA)-compliant institutional review board (IRB)-approved study and were divided into three groups. Group 1 (50 patients) and 2 (50 patients) had undergone MRI performed with gadoxetic acid (fixed 10 ml) at flow rate of 1 and 2 ml/s, respectively. Group 3 (100 patients) had undergone MRI performed with gadobutrol (0.1 mmol/kg) at 1 ml/s. Precontrast and post-contrast (arterial, portal venous, and hepatic venous phases) image degradation was assessed by two blinded independent readers using a four-point rating scale. The numbers of patients with arterial phase image degradation were compared using the Fisher exact test among the three groups.
The incidence of arterial phase image degradation was 12% (6/50) in group 1 and 16% (8/50) in group 2 for both readers, 6% (6/100) for reader 1 and 5% (5/100) for reader 2 in group 3. Group 2 had a higher incidence of arterial phase image degradation when compared with group 3 for reader 2 (p=0.032). Severe arterial phase image degradation, resulting in non-diagnostic image quality, occurred in 4% (2/50) of patients when performed with gadoxetic acid administration at 2 ml/s and 2% (1/50) at 1 ml/s.
A slower injection flow rate has a trend to reduce the incidence and severity of arterial phase image degradation during liver MRI with gadoxetic acid when compared to gadobutrol.
与钆布醇相比，回顾性评估注射流速对钆塞酸二钠（Gd-EOB-DTPA）肝脏磁共振成像（MRI）动脉期图像质量下降的影响。
连续200例接受肝脏MRI检查的患者纳入本符合健康保险流通与责任法案（HIPAA）的机构审查委员会（IRB）批准的研究，并分为三组。第1组（50例患者）和第2组（50例患者）分别以1ml/s和2ml/s的流速静脉注射钆塞酸二钠（固定剂量10ml）进行MRI检查。第3组（100例患者）以1ml/s的流速静脉注射钆布醇（0.1mmol/kg）进行MRI检查。由两名独立的盲法阅片者使用四点评分量表评估对比剂注射前及注射后（动脉期、门静脉期和肝静脉期）的图像质量下降情况。采用Fisher精确检验比较三组动脉期图像质量下降患者的数量。
两名阅片者评估第1组动脉期图像质量下降的发生率分别为12%（6/50），第2组为16%（8/50）；第3组阅片者1为6%（6/100），阅片者2为5%（5/100）。阅片者2评估时，第2组动脉期图像质量下降的发生率高于第3组（p=0.032）。以2ml/s的流速注射钆塞酸二钠时，4%（2/50）的患者出现严重的动脉期图像质量下降，导致图像无法诊断；以1ml/s的流速注射时，2%（1/50）的患者出现上述情况。
与钆布醇相比，较慢的注射流速有降低钆塞酸二钠肝脏MRI动脉期图像质量下降发生率和严重程度的趋势。
